Scientists have discovered a rare inherited mutation in the CDK12 gene linked to aggressive prostate cancer, with all five identified carriers developing metastatic disease between ages 44 and 62. The finding could lead to expanded genetic testing, helping families uncover hidden cancer risks and potentially detect the disease while it is still treatable.